Telomir Pharmaceuticals, Common Stock Investor Sentiment

TELO Stock   4.91  0.03  0.61%   
About 61% of Telomir Pharmaceuticals,'s investor base is looking to short. The analysis of overall sentiment of trading Telomir Pharmaceuticals, Common stock suggests that many investors are alarmed at this time. Telomir Pharmaceuticals,'s investing sentiment overview a quick insight into current market opportunities from investing in Telomir Pharmaceuticals, Common. Many technical investors use Telomir Pharmaceuticals, stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
over two months ago at simplywall.st         
Telomir Pharmaceuticals, Inc.s last weeks 12 percent decline must have disappointed retail investors...
Simply Wall St News at Macroaxis
over two months ago at kalkinemedia.com         
BioMedNewsBreaks Telomir Pharmaceuticals , Science of Longevity Featured in Upcoming Episode of Heal...
news
over two months ago at newswire.com         
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of L...
news
over two months ago at finance.yahoo.com         
Telomir Pharmaceuticals Insider Ups Holding During Year
Yahoo News
over three months ago at prnewswire.com         
TELO Trucks Hires Automotive Design Luminary, Dale Beever, as Director of Design Technical Operation...
prnewswire News
over three months ago at accesswire.com         
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo , to L...
news
over three months ago at finance.yahoo.com         
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo , to L...
Yahoo News
over three months ago at newswire.com         
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo , to L...
news
over three months ago at kalkinemedia.com         
BioMedNewsBreaks Telomir Pharmaceuticals Inc. Appoints Pharmaceutical Innovation Veteran as Chief Sc...
news
over three months ago at news.google.com         
Telomir Pharmaceuticals recruits ex-Synthelabo executive - Investing.com
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Acquisition by Yanez Michelle of 200000 shares of Telomir Pharmaceuticals, at 5.02 subject to Rule 1...
Macroaxis News
over three months ago at finance.yahoo.com         
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Re...
Yahoo News
over three months ago at investorplace.com         
TELO Stock Earnings Telomir Pharmaceuticals Reported Results for Q2 2024
sbwire news
over three months ago at news.google.com         
Telomir Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended J...
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Telomir Pharmaceuticals Mourns the Passing of Chairman and CEODr. Christopher Chapman
Yahoo News
Far too much social signal, news, headlines, and media speculation about Telomir Pharmaceuticals, that are available to investors today. That information is available publicly through Telomir media outlets and privately through word of mouth or via Telomir internal channels. However, regardless of the origin, that massive amount of Telomir data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Telomir Pharmaceuticals, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Telomir Pharmaceuticals, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Telomir Pharmaceuticals,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Telomir Pharmaceuticals, alpha.

Telomir Pharmaceuticals, Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Telomir Pharmaceuticals, Inc.s last weeks 12 percent decline must have disappointed retail investors who have a significant stake
10/01/2024
2
Disposition of 100000 shares by Bay Shore Trust of Telomir Pharmaceuticals, at 3.73 subject to Rule 16b-3
11/21/2024
3
TELO Test Results Continue to Excite
12/03/2024
4
Telomir Pharmaceuticals enters into stock purchase agreement
12/11/2024
5
Telomir Pharmaceuticals Secures 1 Million At 7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20 percent Premium Valuat...
12/16/2024
When determining whether Telomir Pharmaceuticals, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telomir Pharmaceuticals,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telomir Pharmaceuticals, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telomir Pharmaceuticals, Common Stock:
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.78)
Return On Assets
(2.05)
Return On Equity
(17.53)
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.